This $320,000 Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) supports the development of a smoking and e-cigarette cessation treatment using the drug candidate cytisine. The project aims to explore the feasibility of delivering cytisine through electronic vape administration (EVA) as a secondary therapy for individuals seeking to quit smoking and vaping, particularly those who have been unsuccessful with traditional nicotine replacement therapies. The key activities include determining the pharmacokinetics of oral versus vape administration of cytisine, monitoring dopamine levels during nicotine self-administration in a rodent model, and evaluating the abuse liability and potential to reduce nicotine reinforcement using the EVA cytisine approach. This innovative project builds on the awardee's (Spacerx LLC) expertise in smoking cessation drugs and the Henderson Laboratory's specialization in the neuropharmacology of nicotine addiction.
Generated 1/28/25, 7:18 AM